NMRA
Neumora Therapeutics, Inc.
NASDAQ: NMRA · HEALTHCARE · BIOTECHNOLOGY
$1.90
-6.86% today
Updated 2026-06-05
Market cap
$302.01M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.33
Dividend yield
—
52W range
$1 – $4
Volume
1.4M
Neumora Therapeutics, Inc. (NMRA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $1.55M | $2.70M | $668000.00 | — | $5.00M |
| Gross profit | — | — | $-1.55M | $-2.70M | $-668000.00 | — | $-5.00M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | — | $87.13M | $212.78M | $104.75M | $142.72M | $200.93M | $176.06M |
| SG&A | — | $8.39M | $24.55M | $31.12M | $45.48M | $62.54M | $60.09M |
| Operating income | — | $-95.52M | $-237.32M | $-135.87M | $-188.19M | $-263.46M | $-241.16M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | — | $-95.41M | $-236.78M | $-135.28M | $-187.53M | $-262.83M | $-233.37M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-252000.00 | $-95.52M | $-237.32M | $-135.87M | $-188.19M | $-263.46M | $-233.58M |
| Interest expense | — | — | — | — | — | — | $3.22M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | $-99.27M | $-237.31M | $-130.90M | $-235.93M | $-243.79M | $-236.93M |
| Net income growth (YoY) | — | — | -139.1% | +44.8% | -80.2% | -3.3% | +2.8% |
| Profit margin | — | — | — | — | — | — | — |
Frequently asked questions
How much free cash flow does NMRA generate?
NMRA produced $-206.44M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is NMRA's balance sheet healthy?
NMRA holds $182.53M in cash and equivalents against $54.53M in long-term debt, on $103.87M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.